patent.fyi
Applications  /  US 2026/0356818
United States Patent Application Publication

US 2026/0356818 A1

Published
Nov 12, 2026
Filed
Jan 23, 2026
Earliest date on the face
Mar 27, 2019
Classification
C07D 403/04
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Ether oxygen as linker

What ifWhat if A were an ether oxygen connecting the two scaffold fragments?
Claim language“is —CH2—”

The ether oxygen forms a single bond to each scaffold fragment and preserves a one-atom bridge. Its lone pairs provide a hydrogen-bond acceptor at the bridge.

1.2Oxygen in a five-membered ring

What ifWhat if the ring containing Q1, Q2, and Q3 were replaced by a furan ring with oxygen at one ring site?
Claim language“selected from N and CR30”

The furan ring connects the neighboring fragments through carbon atoms at positions 2 and 5. One oxygen lone pair contributes to the aromatic sextet, preserving a planar conjugated ring between the attachment points.

1.3Cyano group at R30

What ifWhat if one R30 group were cyano?
Claim language“selected from hydrogen and halogen”

The nitrile carbon bonds directly to the ring carbon, and the terminal nitrogen provides a hydrogen-bond acceptor. The linear group withdraws electron density from the ring and changes its dipole.

1.8Oxygen-containing ring at R1

What ifWhat if R1 were an oxetan-3-yl group?
Claim language“is cycloalkyl substituted with”

The oxetane attaches to Z through the ring carbon opposite oxygen and provides a compact, saturated four-membered ring. The ring oxygen adds a hydrogen-bond acceptor within that ring.

1.9Phenyl ring at Ar1

What ifWhat if Ar1 were a phenyl ring with CH at both Q4 and Q5?
Claim language“one of Q4 and Q5 is N”

The phenyl ring carries R12 and connects to the neighboring scaffold fragment at the corresponding ring carbons. The six-membered aromatic ring preserves the relative directions of those two bonds, and the two CH sites change the ring dipole.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Enzyme activity control for laboratory instruction

An instructional kit pairs a methylene-linked heterocyclic PanK activator with purified human pantothenate kinase, pantothenate, and ATP. A microplate holds matched reactions containing vehicle, the activator, or the activator with enzyme omitted. A luminescent ADP assay measures ATP turnover and lets students compare enzyme activity across the three conditions.

Component substitution

Carbonyl bridge in place of methylene

A carbonyl group replaces the methylene at A and connects the same two scaffold atoms through its carbon atom. The analog retains the ring atom assignments and peripheral substituents of its methylene-linked reference compound. A purified human PanK assay compares the two compounds at matched concentrations by measuring the rate of phosphopantothenate formation.

Parameter or scale variation

Miniaturized concentration response assay

A 384-well plate holds 10 µL reactions containing purified human PanK, pantothenate, ATP, and the modulator. Ten concentrations span 1 nM to 19.7 µM in threefold steps, with three replicate wells per concentration and 0.2% dimethyl sulfoxide in every reaction. The plate incubates at 25 °C for 15 minutes before a luminescent ADP readout records turnover relative to vehicle and enzyme-free controls.

Combination with existing systems

Direct product measurement by mass spectrometry

An autosampler couples quenched human PanK reactions to a hydrophilic interaction liquid chromatography system and a tandem mass spectrometer. Each reaction contains ATP, pantothenate, and either a methylene-linked modulator or its vehicle. An isotopically labeled phosphopantothenate internal standard is added at quench, and the ratio of product to internal standard is converted to concentration using a calibration curve. Timed samples establish the product formation rate for each condition.

Stable isotope tracing in human cells

Cultured human cells receive isotopically labeled pantothenate and a methylene-linked PanK modulator or vehicle. Replicate wells are harvested at successive time points, and polar metabolites are extracted for liquid chromatography coupled to mass spectrometry. The instrument measures labeled and unlabeled phosphopantothenate and coenzyme A, and the time courses show how treatment changes incorporation of pantothenate into pathway products.

Automated or data-driven variant

Automated profiling across human enzyme isoforms

A liquid handler dispenses one modulator concentration series into separate wells containing purified human PanK1, PanK2, or PanK3. A plate reader records ADP assay signals, and software subtracts enzyme-free background and normalizes each isoform to its vehicle control. The software fits concentration-response curves and reports maximal activity change and half-maximal response concentration for curves with a resolved plateau.

Specific version of a part

Methyl on the amide nitrogen

R10 is methyl in the —NR10C(O)R11 branch, placing one carbon directly on the nitrogen. The resulting tertiary amide retains the carbonyl oxygen as a hydrogen-bond acceptor.

Hydroxymethyl on the amide carbonyl

R11 is hydroxymethyl in the —NR10C(O)R11 branch, giving a —C(O)CH2OH segment. The terminal hydroxyl acts as a hydrogen-bond donor and acceptor.

Geminal fluorines on cyclobutyl

Cy2 is 3,3-difluorocyclobutyl in the amide branch and attaches to the carbonyl carbon through ring position 1. Both fluorines occupy ring position 3, opposite the attachment point.

Methyl on the sulfonyl sulfur

R20 is methyl, giving an Ar1—SO2—CH3 substituent. Both sulfonyl oxygens act as hydrogen-bond acceptors, and the methyl carbon bonds directly to sulfur.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 9,056,832 B2
Published
Jun 16, 2015
Filed
Sep 16, 2011
Class
C07D 213/30
Document BUS 9,115,120 B2
Published
Aug 25, 2015
Filed
Aug 23, 2013
Class
C07D 413/04
Claim 1
Document A
Document B
1.1A is —CH2—
1.2wherein each of Q1, Q2, and Q3 is independently selected from N and CR30
A compound of structural Formula II or a salt thereof, wherein: B is selected from the group consisting of X2, X4, and X5 are independently selected from the group consisting of CR21, N, O, and S, and wherein X2, X4, and X5, taken together, form a 5-membered heteroaryl;
B · US 9,115,120 B2 · claim 1
1.3wherein each occurrence of R30, when present, is independently selected from hydrogen and halogen
R1a and R1b, which are identical or different, are selected from the group consisting of: a) hydrogen; b) halogen; c) hydroxy; d) cyano; e) optionally substituted alkyl; f) alkoxy; g) haloalkoxy; and h) haloalkyl;
A · US 9,056,832 B2 · claim 1
R21 is selected from the group consisting of null, hydrogen, deuterium, halogen, alkyl, haloalkyl, perhaloalkyl, heteroalkyl, hydroxyalkyl, cyano, hydroxy, alkoxy, haloalkoxy, perhaloalkoxy, alkylthio, amino, alkylamino, and dialkylamino;
B · US 9,115,120 B2 · claim 1
1.4wherein Z is a structure selected from: wherein R1 is selected from —NH2, C1-C4 alkyl, (C1-C4) alkylamino, (C1-C4)(C1-C4) dialkylamino, —NR10C(O)R11, —NR10SO2R11, and Cy1
R1 is selected from the group consisting of —Y2-alkyl-N(R4)R5, hydrogen, deuterium, halogen, alkyl, alkenyl, haloalkyl, perhaloalkyl, heteroalkyl, hydroxyalkyl, aminoalkyl, acyl, carboxylalkyl, carbonyl, carboxyl, cyano, hydroxy, alkoxy, haloalkoxy, perhaloalkoxy, oxo, alkylthio, thiolalkyl, sulfonyl, sulfonamido, alkylsulfonyl, amino, amido, alkylamino, dialkylamino, nitro, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, cycloalkyloxy, aryloxy, heterocycloalkyloxy, heteroary
B · US 9,115,120 B2 · claim 1
1.5wherein R10, when present, is selected from hydrogen and C1-C4 alkyl
X is selected from the group consisting of: a) —O—; b) —S—; c) —SO—; d) —SO2— e) —NR4; f) —SO2NH—; and g) —NHSO2—; wherein: R4 is selected from the group consisting of hydrogen and optionally substituted alkyl;
A · US 9,056,832 B2 · claim 1
The term “lower amino,” as used herein, alone or in combination, refers to —NRR′, wherein R and R′ are independently selected from the group consisting of hydrogen, lower alkyl, and lower heteroalkyl, any of which may be optionally substituted.
B · US 9,115,120 B2 · ¶ 241
1.6wherein R11, when present, is selected from hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, —(C1-C4 alkyl)-OC(O)—(C1-C4 alkyl), and Cy2
R24a is selected from the group consisting of unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted aryl, and unsubstituted heteroaryl; R24b is selected from the group consisting of unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted aryl, and unsubstituted heteroaryl; t and u are each independently 0, 1, 2, or 3; and v is 1, 2, or 3; wherein: 1) when G is G-1, then E is hydroxyalkyl, E-1, or E-5; or 2) when E is hydrogen, then G is G-2, G-3, or G-4.
A · US 9,056,832 B2 · claim 1
R4 and R5 are independently selected from the group consisting of hydrogen, deuterium, alkyl, alkenyl, alkynyl, haloalkyl, perhaloalkyl, heteroalkyl, hydroxyalkyl, acyl, carbonyl, carboxyl, alkoxy, haloalkoxy, perhaloalkoxy, alkylsulfonyl, sulfonamido, amido, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, cycloalkylalkyl, arylalkyl, heterocycloalkylalkyl, and heteroarylalkyl, or R4 and R5, taken together, form a heterocyloalkyl or heteroaryl, any of which can be optionally s
B · US 9,115,120 B2 · ¶ 29
1.7wherein Cy2, when present, is cycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, —NO2, —CN, —OH, —SH, —NH2, C1-C4 alkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino
For the purpose of the present disclosure, the term “optionally substituted cycloalkyl” as used by itself or as part of another group means that the cycloalkyl as defined above is either unsubstituted or substituted with one, two, or three substituents independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsu
A · US 9,056,832 B2 · ¶ 530
1.8wherein Cy1, when present, is cycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, —NO2, —CN, —OH, —SH, —NH2, C1-C4 alkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino
G is: wherein: R5a and R5b, which are identical or different, are selected from the group consisting of: a) hydrogen; b) unsubstituted alkyl; c) cycloalkyl, which is unsubstituted or substituted with one, two, or three substituents independently selected from the group consisting of halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, al
A · US 9,056,832 B2 · claim 1
1.9wherein Ar1 is a structure wherein one of Q4 and Q5 is N and one of Q4 and Q5 is CH
1.10wherein R12 is selected from halogen, —CN, —NO2, C1-C4 polyhaloalkyl, and —SO2R20
E is selected from the group consisting of: a) hydrogen; b) heteroaryl, which is unsubstituted or substituted with one to four substituents independently selected from the group consisting of halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, cycloalkyl, alke
A · US 9,056,832 B2 · claim 1
R3 is selected from the group consisting of hydrogen, deuterium, halogen, alkyl, haloalkyl, perhaloalkyl, heteroalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, acyl, carbonyl, carboxyl, cyano, cyanoalkyl, hydroxy, alkoxy, haloalkoxy, perhaloalkoxy, alkoxyalkoxy, hydroxyalkoxy, oxo, alkylthio, mercaptyl, thiol, haloalkylthio, perhaloalkylthio, cyanoalkylthio, haloalkylsulfonyl, alkylsulfonyl, alkoxyalkylsulfonyl, cyanoalkylsulfonyl, sulfonate, sulfonamido, amino, amido, alkylami
B · US 9,115,120 B2 · ¶ 27
1.11wherein R20, when present, is selected from hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, —(C1-C4 alkyl)-OC(O)—(C1-C4 alkyl), and Cy3
1.12wherein Cy3, when present, is cycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, —NO2, —CN, —OH, —SH, —NH2, C1-C4 alkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino, provided that when R1 is Cy1, Q4 is N, and Q5 is CH, then R12 is polyhaloalkyl, or a pharmaceutically acceptable salt thereof.

An empty cell means only that no passage was reproduced there.

Statements in these documents
The invention relates to novel substituted pyridine compounds and the use of these compounds as blockers of voltage-gated sodium (Na+) channels.
A · US 9,056,832 B2 · ¶ 2
Methods to inhibit HIF pathway activity through the degradation of the HIFα protein subunits in a human or animal subject are also provided for the treatment of diseases mediated by HIF pathway activity.
B · US 9,115,120 B2 · ¶ 2
HIF mediated survival of cells in hypoxia is a major contributor to resistance to therapies, lack of durable response and the foundation of residual disease.
B · US 9,115,120 B2 · ¶ 8
Cite aspatent.fyi, US 2026/0356818 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356818/, SHA-256 1df3060dce3f4dbc4075331ccc80217ad826e072a5b3620155083f576582584f
First published
Permanent addresshttps://patent.fyi/US20260356818/
Content fingerprint (SHA-256)1df3060dce3f4dbc4075331ccc80217ad826e072a5b3620155083f576582584f
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi